2,2-difluoro-2-(quinolin-2-yl)acetic acid ethyl ester | 294181-97-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 2,2-difluoro-2-(quinolin-2-yl)acetic acid ethyl ester
• 英文别名: 2,2-difluoro-2-(2-quinolinyl)acetic acid ethyl ester；ethyl 2,2-difluoro-2-(quinolin-2-yl)acetate；ethyl 2,2-difluoro-2-(2-quinolinyl)acetate；Ethyl 2,2-difluoro-2-quinolin-2-ylacetate
• CAS: 294181-97-8
• 化学式: C₁₃H₁₁F₂NO₂
• 分子量: 251.233
• InChiKey: JYKWDCWQFNQIQB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  39.2
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2,2-difluoro-2-(quinolin-2-yl)acetic acid ethyl ester 在 potassium hydroxide 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 6.0h， 生成
  参考文献：
  名称：

  ジフルオロメチレン化合物の製造方法

  摘要：

  提供一种制备二氟甲基化合物的方法，包括将由式（Ia）代表的芳基二氟乙酸盐与由式（IIa）代表的芳基亲电试剂在式（IIIa）代表的反应条件下进行反应。其中，R为CN、NO2、C（O）OC2H5、COCH3或Cl；m为1或2的整数；M为Li、Na、K、Rb或Cs；Ar为可任意取代的苯基或苯基取代的烷基（烷基的C为1~5），Ar可选择自-Cl基、-OCH3基和-C（O）OC2H5基的取代基。

  公开号：

  JP2015071547A
• 作为产物：
  描述：

  2-碘喹啉 、 2-（三甲基硅基）-2，2-二氟乙酸乙酯 在 potassium fluoride 、 copper(l) iodide 作用下， 以 二甲基亚砜 为溶剂， 反应 15.0h， 以87%的产率得到2,2-difluoro-2-(quinolin-2-yl)acetic acid ethyl ester
  参考文献：
  名称：

  A New Method for Aromatic Difluoromethylation: Copper-Catalyzed Cross-Coupling and Decarboxylation Sequence from Aryl Iodides

  摘要：

  A new methodology for aromatic difluoromethylation is described. Aryl iodides reacted with alpha-silyldifluoroacetates upon treatment with copper catalyst in DMSO or DME to give the corresponding aryldifluoroacetates in moderate to good yields. The subsequent hydrolysis of aryldifluoroacetates and KF-promoted decarboxylation afforded a variety of difluoromethyl aromatics.

  DOI：

  10.1021/ol202289z

文献信息

• [EN] NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A<br/>[FR] NOUVEAUX COMPOSÉS INHIBITEURS DE LA PHOSPHODIESTÉRASE DE TYPE 10A
  申请人：ABBVIE DEUTSCHLAND

  公开号：WO2014140184A1

  公开（公告）日：2014-09-18

  The present invention relates to compounds of the formula (I), the N-oxides, tautomers, the prodrugs and the pharmaceutically acceptable salts thereof. In formula I the variables Het, A, X, Y, Z, R1, R2, R3, R4, R5 and Q are as defined in the claims. The compounds of the formula I, the N-oxides, tautomers, the prodrugs and the pharmaceutically acceptable salts thereof are inhibitors of phosphodiesterase type 10A. Thus, the invention also relates to the use of the compounds of the formula I, the N-oxides, tautomers, the prodrugs and the pharmaceutically acceptable salts thereof for the manufacture of a medicament and which thus are suitable for treating or controlling of medical disorders selected from neurological disorders and psychiatric disorders, for ameliorating the symptoms associated with such disorders and for reducing the risk of such disorders.

  本发明涉及通式(I)的化合物、其N-氧化物、互变异构体、前药及其药学上可接受的盐。在式I中，变量Het、A、X、Y、Z、R1、R2、R3、R4、R5和Q如权利要求中所定义。通式I的化合物、其N-氧化物、互变异构体、前药及其药学上可接受的盐是磷酸二酯酶10A的抑制剂。因此，本发明还涉及通式I的化合物、其N-氧化物、互变异构体、前药及其药学上可接受的盐用于制备药物的用途，这些药物适用于治疗或控制选自神经性疾病和精神性疾病的医疗病症，以改善与这些病症相关的症状，并降低这些病症的风险。
• New Antifungal 1,2,4-Triazoles with Difluoro(heteroaryl)methyl Moiety.
  作者：Hiromichi ETO、Yasushi KANEKO、Takao SAKAMOTO

  DOI：10.1248/cpb.48.982

  日期：——

  New 1, 2, 4-triazoles (1) having a difluoro(heteroaryl)methyl moiety were designed and synthesized via 1-aryl-2, 2-difluoro-2-(heteroaryl)ethanones (2), which were prepared by two routes starting from the reaction of ethyl 2, 2-difluoro(heteroaryl)acetate with phenyllithiums (Route A) and from the reaction of chlorodifluoro(heteroaryl)methane with benzaldehydes (Route B). The compounds 1 except for 1g show antifungal activities against yeasts and filamentous fungi in vitro, especially (+)-1f have equal or superior activities compared to those of itraconazole.

  新型1, 2, 4-三氮唑化合物（1），具有二氟(杂环基)甲基结构，通过1-芳基-2, 2-二氟-2-(杂环基)乙酮（2）的设计与合成而得，该中间体通过两种途径制备：一种是从乙基2, 2-二氟(杂环基)乙酸酯与苯基锂反应开始（途径A），另一种则是从氯二氟(杂环基)甲烷与苯甲醛反应开始（途径B）。除了化合物1g外，所有化合物1均表现出体外抗真菌活性，尤其是(+)-1f，其活性与伊曲康唑相当甚至更优。
• NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A
  申请人：Geneste Hervé

  公开号：US20130005705A1

  公开（公告）日：2013-01-03

  The present invention relates to novel carboxamide compounds, pharmaceutical compositions containing them, and their use in therapy. The compounds possess valuable therapeutic properties and are particularly suitable for treating or controlling medical disorders selected from neurological disorders and psychiatric disorders, for ameliorating the symptoms associated with such disorders and for reducing the risk of such disorders.

  本发明涉及新型的氨基甲酸酰胺化合物、含有它们的药物组合物及其在治疗中的应用。这些化合物具有宝贵的治疗特性，特别适用于治疗或控制神经疾病和精神疾病，用于改善与这些疾病相关的症状，并用于降低这些疾病的风险。
• Substituted isoquinolines and phthalazines as inhibitors of phosphodiesterase type 10A
  申请人：Abbott GmbH & Co. KG

  公开号：US09273068B2

  公开（公告）日：2016-03-01

  The present invention relates to novel compounds of the formula (I), wherein Het, A, Q, X1, X2, X3, R1 and R2 are defined in the specification, which are inhibitors of phosphodiesterase type 10A and to their use for the manufacture of a medicament and which thus are suitable for treating or controlling of medical disorders selected from neurological disorders and psychiatric disorders, for ameliorating the symptoms associated with such disorders and for reducing the risk of such disorders.

  本发明涉及公式（I）的新化合物，其中Het，A，Q，X1，X2，X3，R1和R2在规范中有定义，它们是磷酸二酯酶10A的抑制剂，并且用于制造药物，因此适用于治疗或控制选择的医学疾病，包括神经系统疾病和精神障碍，改善与此类疾病相关的症状，并降低此类疾病的风险。
• Inhibitor compounds of phosphodiesterase type 10A
  申请人：AbbVie Deutschland GmbH & Co. KG

  公开号：US09163019B2

  公开（公告）日：2015-10-20

  The present invention relates to compounds of the formula I, the N-oxides, tautomers, the prodrugs and the pharmaceutically acceptable salts thereof: In formula I the variables Het, A, X, Y, Z, R1, R2, R3, R4, R5 and Q are as defined in the claims. The compounds of the formula I, the N-oxides, tautomers, the prodrugs and the pharmaceutically acceptable salts thereof are inhibitors of phosphodiesterase type 10A. Thus, the invention also relates to the use of the compounds of the formula I, the N-oxides, tautomers, the prodrugs and the pharmaceutically acceptable salts thereof for the manufacture of a medicament and which thus are suitable for treating or controlling of medical disorders selected from neurological disorders and psychiatric disorders, for ameliorating the symptoms associated with such disorders and for reducing the risk of such disorders.

  本发明涉及公式I的化合物，其N-氧化物，互变异构体，前药和药学上可接受的盐：在公式I中，变量Het，A，X，Y，Z，R1，R2，R3，R4，R5和Q的定义如所述。公式I的化合物，其N-氧化物，互变异构体，前药和药学上可接受的盐是磷酸二酯酶10A的抑制剂。因此，本发明还涉及使用公式I的化合物，其N-氧化物，互变异构体，前药和药学上可接受的盐制造药物，适用于治疗或控制神经系统和精神障碍，改善与此类障碍相关的症状，降低此类障碍的风险。